Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues

Free Radical Biology and Medicine

Volumn 29, Issue 3-4, 2000, Pages 246-253

  Siegel, David ^a   Ross, David ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Chemoprevention; DT diaphorase; Endothelium; Epithelium; F ree radicals; Immunohistochemistry; NAD(P)H; quinone oxidoreductase 1 (NQO1); Quinone reductase; Tumor

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADRENAL TUMOR; ARTICLE; BREAST DUCT; BREAST TUMOR; COLON MUCOSA; COLON TUMOR; CORNEA EPITHELIUM; HEART MUSCLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LENS EPITHELIUM; LUNG NON SMALL CELL CANCER; OVARY TUMOR; PARASYMPATHETIC GANGLION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; THYROID FOLLICLE; THYROID TUMOR; VASCULAR ENDOTHELIUM;

ANTIBODIES, MONOCLONAL; CHEMILUMINESCENCE; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM PROTEINS; NEOPLASMS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033801337     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(00)00310-5     Document Type: Article

References (51)

1. Ernster L., Navazio F. Soluble diaphorase in animal tissues. Acta Chem. Scand. 12:1958;595-602.
2. Ernster L. Diaphorase activities in liver cytoplasmic fractions. Fed. Proc. 17:1958;216.
3. Ernster L. DT-diaphorase a historical review . Chemica Scripta. 27A:1987;1-13.
4. Chesis P.L., Levin D.E., Smith M.T., Ernster L., Ames B.N. Mutagenicity of quinones pathways of metabolic activation and detoxification . Proc. Natl. Acad. Sci. USA. 81:1984;1696-1700.
5. Lind C., Hochstein P., Ernster L. DT-Diaphorase as a quinone reductase a cellular control device against semiquinone and superoxide radical formation . Arch. Biochem. Biophys. 216:1982;178-185.
6. Thor H., Smith M.T., Hartzell P., Bellomo G., Jewell S.A., Orrenius S. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implication of oxidative stress in intact cells. J. Biol. Chem. 257:1982;12419-12425.
7. Huggins C., Fukunishi R. Induced protection of adrenal cortex against 7,12- dimethylbenz(a)anthracene. Influence of ethionine. Induction of menadione reductase. Incorporation of thymidine-H3. J. Exp. Med. 119:1964;923-942.
8. Benson A.M., Hunkler M.J., Talalay P. Increase of NAD(P)H:quinone reductase by dietary antioxidants possible role in protection against carcinogenesis and toxicity . Proc. Natl. Acad. Sci. USA. 77:1980;5216-5220.
9. Talalay P., De Long M.J., Prochaska H.J. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc. Natl. Acad. Sci. USA. 85:1988;8261-8265.
10. Trush M.A., Twerdok L.E., Rembish S.J., Zhu H., Li Y.B. Analysis of target cell susceptibility as a basis for the development of a chemoprotective strategy against benzene-induced hematotoxicities. Environ. Health Perspect. 104:(Suppl. 6):1996;1227-1234.
11. Beyer R.E., Segura-Aguilar J., Di Bernardo S., Cavazzoni M., Fato R., Fiorentini D., Galli M., Setti M., Landi L., Lenaz G. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc. Natl. Acad. Sci. USA. 93:1996;2528-2532.
12. Siegel D., Bolton E.M., Burr J.A., Liebler D.C., Ross D. The reduction of alpha-tocopherolquinone by human NAD(P)H:quinone oxidoreductase the role of alpha-tocopherol hydroquinone as a cellular antioxidant . Mol. Pharmacol. 52:1997;300-305.
13. Traver R.D., Siegel D., Beall H.D., Phillips R.M., Gibson N.W., Franklin W.A., Ross D. Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). Br. J. Cancer. 75:1997;69-75.
14. Siegel D., McGuinness S.M., Winski S., Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics. 9:1999;113-121.
15. Schulz W.A., Krummeck A., Rosinger I., Eickelmann P., Neuhas C., Ebert T., Schmitz-Dräger B., Sies H. Increased frequency of a null allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics. 7:1997;235-239.
16. Larson R.A., Wang Y., Banerjee M., Wiemels J., Hartford C., Beau M.M., Smith M.T. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 94:1999;803-807.
17. Schulz W.A., Krummeck A., Rosinger I., Schmitz-Drager B.J., Sies H. Predisposition toward urolithiasis associated with the NQO1 null-allele. Pharmacogenetics. 8:1998;453-454.
18. Clairmont A., Sies H., Ramachandran S., Lear J.T., Smith A.G., Bowers B., Jones P.W., Fryer A.A., Strange R.C. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci . Carcinogenesis. 20:1999;1235-1240.
19. Wiemels J.L., Pagnamenta A., Taylor G.M., Eden O.B., Alexander F.E., Greaves M.F. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res. 59:1999;4095-4099.
20. Rothman N., Smith M.T., Hayes R.B., Traver R.D., Hoener B.A., Campleman S., Li G.L., Dosemeci M., Linet M., Zhang L.P., Xi L.Q., Wacholder S., Lu W., Meyer K.B., Titenko-Holland N., Stewart J.T., Yin S.N., Ross D. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQ01[60][9]C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 57:1997;2839-2842.
21. Steiner M., Hillenbrand M., Borkowsi M., Seiter H., Schuff-Werner P. 609 C→T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia. Cancer Lett. 135:1999;67-71.
22. Hajos A.K.D., Winston G.W. Dinitropyrene nitroreductase activity of purified NAD(P)H:quinone oxidoreductase role in rat liver cytosol and induction by Aroclor-1254 pretreatment . Carcinogenesis. 12:1991;697-702.
23. Wiencke J.T., Spitz M.R., McMillan A., Kelsey K.T. Lung cancer in Mexican-Americans and African-Americans is associated with the wild type genotype of the NAD(P)H:quinone oxidoreductase polymorphism. Cancer Epidemiol. Biol. Prev. 6:1997;87-92.
24. Chen, H.; Lum, A.; Seifried, A.; Wilkens, L. R.; Le Marchand, L. Association of the NAD(P)H:quinone oxidoreductase 609C→T polymorphism with a decreased lung cancer risk. Cancer Res. 59:3045-3048; 1999.
25. Mekhail-Ishak K., Hudson N., Tsao M.S., Batist G. Implications for therapy of drug metabolizing enzymes in human colon cancer. Cancer Res. 49:1989;4866-4869.
26. Schlager J.J., Powis G. Cytosolic NAD(P)H:quinone acceptor oxidoreductase in human normal and tumor tissue. Effects of cigarette smoking and alcohol. Int. J. Cancer. 45:1990;403-409.
27. Smitskamp-Wilms E., Giaccone G., Pinedo H.M., Van der Laan B.F.A.M., Peters G.J. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents. Br. J. Cancer. 72:1995;917-921.
28. Malkinson A.M., Siegel D., Forrest G.L., Gazdar A.F., Oie H.K., Chan D.C., Bunn P.A., Mabry M., Dykes D.J., Harrison S.D. Jr, Ross D. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma relationship to the response of lung tumor xenografts to mitomycin C . Cancer Res. 52:1992;4752-4757.
29. Mikami K., Naito M., Ishiguro T., Yano H., Tomida A., Yamada T., Tanaka N., Shirakusa T., Tsuruo T. Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers advanced tumors express greater levels of DT-diaphorase . Jpn. J. Cancer Res. 89:1998;910-915.
30. Workman P., Walton M.I. Enzyme-directed bioreductive drug development. Adams G.E., Breccia A., Fielden E.M., Wardman P. Selective activation of drugs by redox processes. 1990;173-191 Plenum, New York.
31. Workman P. Enzyme-directed bioreductive drug development revisited a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase . Oncol. Res. 6:1994;461-475.
32. Ross D., Siegel D., Beall H., Prakash A.S., Mulcahy R.T., Gibson N.W. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metastasis Rev. 12:1993;83-101.
33. Ross D., Beall H., Traver R.D., Siegel D., Phillips R.M., Gibson N.W. Bioactivation of quinones by DT-diaphorase. Molecular, biochemical and chemical studies. Oncol. Res. 6:1994;493-500.
34. Siegel D., Gibson N.W., Preusch P.C., Ross D. Metabolism of mitomycin C by DT-diaphorase role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells . Cancer Res. 50:1990;7483-7489.
35. Winski S., Hargreaves R.H.J., Butler J., Ross D. A new screening system for NAD(P)H:quinone oxidoreductase(NQO1)-directed antitumor quinones. Identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin. Cancer Res. 4:1998;3083-3088.
36. Siegel D., Franklin W.A., Ross D. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin. Cancer Res. 4:1998;3083-3088.
37. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
38. Davies K.J.A., Doroshow J. Redox cycling of anthracyclines by cardiac mitochondria I anthracycline radical formation by NADH dehydrogenase. J. Biol. Chem. 261:1986;3060-3067.
39. Schultzberg M., Segura-Aguilar J., Lind C. Distribution of DT-diaphorase in the rat brain biochemical and immunohistochemical studies . Neuroscience. 27:1988;763-776.
40. Segura-Aguilar J., Lind C. On the mechanism of the Mn-induced neurotoxicity of dopamine prevention of quinone derived oxygen toxicity by DT-diaphorase and superoxide dismutase . Chem. Biol. Interact. 72:1989;309-324.
41. Smith D., Martin L.F., Wallin R. Human DT-diaphorase, a potential cancer protecting enzyme. Its purification from abdominal adipose tissue. Cancer Lett. 42:1988;103-112.
42. Wermuth B., Platts K.L., Seidel A., Oesch F. Carbonyl reductase provides the enzymatic basis of quinone detoxication in man. Biochem. Pharmacol. 35:1986;1277-1282.
43. Sharkis D.H., Swenson R.P. Purification by cibacron blue F3GA dye affinity chromatography and comparison of NAD(P)H:quinone reductase (E. C. 1. 6. 99. 2) from rat liver cytosol and microsomes. Biochem. Biophys. Res. Commun. 161:1989;434-441.
44. Cresteil T., Jaiswal A.K. High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem. Pharmacol. 42:1991;1021-1027.
45. 1 gene. Proc. Natl. Acad. Sci. USA. 93:1996;14960-14965.
46. Joseph P., Xie T., Xu Y., Jaiswal A.K. NAD(P)H quinone oxidoreductase (DT-diaphorase). Expression, regulation and role in cancer. Oncol. Res. 6:1994;525-532.
47. Kepa J.K., Ross D. DT-diaphorase activity in NSCLC and SCLC cell lines a role for fos/jun regulation . Br. J. Cancer. 79:1999;1679-1684.
48. Ross D., Siegel D., Schattenberg D.G., Moran J.L. Cell-specific metabolism in benzene toxicity. A metabolic basis for benzene induced toxicity at the level of the progenitor cell in human bone marrow. Toxicologist. 16:1996;1740.
49. Moran J.L., Siegel D., Ross D. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc. Natl. Acad. Sci. USA. 96:1999;8150-8155.
50. Ross D., Siegel D., Schattenberg D.G., Sun X.M.M., Moran J.L. Cell-specific activation and detoxification of benzene metabolites in mouse and human bone marrow identification of target cells and a potential role for modulation of apoptosis in benzene toxicity . Environ. Health Perspect. 104:(Suppl. 6):1996;1177-1182.
51. Verweij J., Aamdal S., Schellens J., Koier I., Lund B. Clinical studies with E09, a new indoloquinone bioreductive alkylating cytotoxic agent. Oncol. Res. 6:1994;519-523.